SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LOS ANGELES, May 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX) concerning possible violations of federal securities laws between March 30, 2017 and May 11, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced that the report was withdrawn due to “material inaccuracies.” On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. When this information was announced, Akari shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
